https://pepsreview.com/articles/oral-obesity-drugs-south-korea-approval-filings PepsReview en 2026-09-17 oral GLP-1, South Korea obesity drug approval, orforglipron, oral semaglutide, MFDS, GLP-1 market Asia, weight loss pill, Novo Nordisk Eli Lilly https://pepsreview.com/articles/novo-returns-once-monthly-glp-1-rights-to-ascendis-pipeline-reset PepsReview en 2026-09-17 Novo Nordisk, Ascendis Pharma, GLP-1 pipeline, once-monthly semaglutide, obesity drug development, pharmaceutical licensing, TransCon technology https://pepsreview.com/articles/glp-1-makers-paid-270000-doctors-federal-disclosures-show PepsReview en 2026-09-17 GLP-1 payments, Open Payments, Eli Lilly, Novo Nordisk, physician disclosure, weight-loss drug marketing, prescribing conflicts, pharmaceutical transparency https://pepsreview.com/articles/glp-1-brain-disorder-thiamine-deficiency-study PepsReview en 2026-09-17 GLP-1 brain disorder, thiamine deficiency, Wernicke encephalopathy, semaglutide safety, weight-loss drug risks, vitamin B1, adverse events, neurologic complications https://pepsreview.com/articles/no-fda-approved-glp-1-patch-exists-unregulated-transdermal-claims-explained PepsReview en 2026-09-16 GLP-1 patch, FDA approval, transdermal semaglutide, weight loss patch, peptide verification, counterfeit GLP-1, semaglutide, tirzepatide https://pepsreview.com/articles/legal-campaigns-recruit-wegovy-users-as-semaglutide-naion-claims-expand PepsReview en 2026-09-16 semaglutide, Wegovy, NAION, GLP-1 litigation, vision loss, peptide testing, incretin safety, Novo Nordisk https://pepsreview.com/articles/thailand-makes-glp-1-injections-prescription-only PepsReview en 2026-09-15 Thailand GLP-1 prescription, semaglutide regulation, weight-loss injection pens, Thai FDA, counterfeit peptides, GLP-1 enforcement, prescription-only https://pepsreview.com/articles/counterfeit-semaglutide-peptide-hospitalizes-new-zealand-user PepsReview en 2026-09-15 counterfeit semaglutide, peptide safety, unregulated injectables, GLP-1 counterfeit, independent testing, certificate of analysis, peptide verification https://pepsreview.com/articles/novo-nordisk-rebrands-as-novo-glp-1-strategic-reset PepsReview en 2026-09-15 Novo Nordisk rebrand, Novo, GLP-1 market, Wegovy, Ozempic, Zepbound competition, semaglutide, peptide safety